BHK Cell Line - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

BHK Cell Line

The Experts below are selected from a list of 207 Experts worldwide ranked by ideXlab platform

Zhang Jingang – One of the best experts on this subject based on the ideXlab platform.

  • construction of coagulant factor vii gene expression vector and expression in BHK Cell Line
    Progress in Biotechnology, 2005
    Co-Authors: Zhang Jingang

    Abstract:

    In order to achieve the expression of recombinant human coagulant factor Ⅶ (rhF Ⅶ) in mammalian Cell Lines and to study its biological activity. The hF Ⅶ cDNA was amplified using PCR method, and the expression vector was constructed by subcloning method. After identification by DNA sequencing and obtaining a correct recombinant vector, the recombinant expression vector pIRES-F Ⅶ was transfected into BHK-21 Cell Line by means of lipofectin procedure. The resultant transfected Cells were selected by G418.The positive Cell clones were cultured and the culture supernatants were collected for identification by SDS-PAGE, Western blot and bioassays. The results showed that the bioactive rhF Ⅶ was expressed in BHK-21 Cell Line, and laid a foundation for further research.

Pierre Brugières – One of the best experts on this subject based on the ideXlab platform.

  • Neuroprotective gene therapy for Huntington’s disease, using polymer-encapsulated Cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study.
    Human Gene Therapy, 2004
    Co-Authors: Jocelyne Bloch, Anne-catherine Bachoud-lévi, Nicole Déglon, Jean-paul Nguyen, Catherine Bourdet, L. Winkel, Philippe Remy, Jean-pascal Lefaucheur, Stéphane Palfi, Pierre Brugières

    Abstract:

    Huntington’s disease (HD) is a monogenic neurodegenerative disease that affects the efferent neurons of the striatum. The protracted evolution of the pathology over 15 to 20 years, after clinical onset in adulthood, underscores the potential of therapeutic tools that would aim at protecting striatal neurons. Proteins with neuroprotective effects in the adult brain have been identified, among them ciliary neurotrophic factor (CNTF), which protected striatal neurons in animal models of HD. Accordingly, we have carried out a phase I study evaluating the safety of intracerebral administration of this protein in subjects with HD, using a device formed by a semipermeable membrane encapsulating a BHK Cell Line engineered to synthesize CNTF. Six subjects with stage 1 or 2 HD had one capsule implanted into the right lateral ventricle; the capsule was retrieved and exchanged for a new one every 6 months, over a total period of 2 years. No sign of CNTF-induced toxicity was observed; however, depression occurred in three subjects after removal of the last capsule, which may have correlated with the lack of any future therapeutic option. All retrieved capsules were intact but contained variable numbers of surviving Cells, and CNTF release was low in 13 of 24 cases. Improvements in electrophysiological results were observed, and were correlated with capsules releasing the largest amount of CNTF. This phase I study shows the safety, feasibility, and tolerability of this gene therapy procedure. Heterogeneous Cell survival, however, stresses the need for improving the technique.

  • Neuroprotective Gene Therapy for Huntington’s Disease Using a Polymer Encapsulated BHK Cell Line Engineered to Secrete Human CNTF
    Human Gene Therapy, 2000
    Co-Authors: Anne-catherine Bachoud-lévi, Nicole Déglon, Jean-paul Nguyen, Jocelyne Bloch, Catherine Bourdet, L. Winkel, Philippe Remy, Moses Goddard, J.-p. Lefaucheur, Pierre Brugières

    Abstract:

    Huntington’s disease (HD) is an autosomal dominant genetic disease with devastating clinical effects on cognitive, psychological, and motor functions. These clinical symptoms primarily relate to the progressive loss of medium-spiny GABA-ergic neurons of the striatum. There is no known treatment to date. Several neurotrophic factors have, however, demonstrated the capacity to protect striatal neurons in various experimental models of HD. This includes the ciliary neurotrophic factor (CNTF), the substance examined in this protocol. An ex vivo gene therapy approach based on encapsulated genetically modified BHK Cells will be used for the continuous and long-term intracerebral delivery of CNTF. A device, containing up to 106 human CNTF-producing BHK Cells surrounded by a semipermeable membrane, will be implanted into the right lateral ventricle of 6 patients. Capsules releasing 0.15-0.5 μg CNTF/day will be used. In this phase I study, the principal goal will be the evaluation of the safety and tolerability of…

  • neuroprotective gene therapy for huntington s disease using a polymer encapsulated BHK Cell Line engineered to secrete human cntf
    Human Gene Therapy, 2000
    Co-Authors: Annecatherine Bachoudlevi, Nicole Déglon, Jean-paul Nguyen, Jocelyne Bloch, Catherine Bourdet, L. Winkel, Philippe Remy, Moses Goddard, J.-p. Lefaucheur, Pierre Brugières

    Abstract:

    Huntington’s disease (HD) is an autosomal dominant genetic disease with devastating clinical effects on cognitive, psychological, and motor functions. These clinical symptoms primarily relate to the progressive loss of medium-spiny GABA-ergic neurons of the striatum. There is no known treatment to date. Several neurotrophic factors have, however, demonstrated the capacity to protect striatal neurons in various experimental models of HD. This includes the ciliary neurotrophic factor (CNTF), the substance examined in this protocol. An ex vivo gene therapy approach based on encapsulated genetically modified BHK Cells will be used for the continuous and long-term intracerebral delivery of CNTF. A device, containing up to 106 human CNTF-producing BHK Cells surrounded by a semipermeable membrane, will be implanted into the right lateral ventricle of 6 patients. Capsules releasing 0.15-0.5 μg CNTF/day will be used. In this phase I study, the principal goal will be the evaluation of the safety and tolerability of…

Akira Nishizono – One of the best experts on this subject based on the ideXlab platform.

  • Molecular analysis of the mutational effects of Thai street rabies virus with increased virulence in mice after passages in the BHK Cell Line
    Archives of Virology, 2012
    Co-Authors: Phatthamon Virojanapirom, Pakamatz Khawplod, Artikaya Sawangvaree, Supaporn Wacharapluesadee, Thiravat Hemachudha, Kentaro Yamada, Kinjiro Morimoto, Akira Nishizono

    Abstract:

    QS-BHK-P7, street rabies virus, after passages in the BHK Cell Line, had an in vitro phenotype that distinguished it from its parental virus. Both viruses caused lethal infection in mice by central nervous system inoculation; however, only QS-BHK-P7 killed mice by the intramuscular route. We found four mutations, S23R and H424P in ectodomain of the glycoprotein (G), I1711 V in the polymerase genes, and another at the non-coding region between the phosphoprotein and matrix protein genes of QS-BHK-P7. None of the mutations in the G gene occurred in previously reported pathogenic determinants. The roles of mutations in particular non-coding regions remain to be elucidated.